342 related articles for article (PubMed ID: 29670288)
1. Structural basis of ligand binding modes at the neuropeptide Y Y
Yang Z; Han S; Keller M; Kaiser A; Bender BJ; Bosse M; Burkert K; Kögler LM; Wifling D; Bernhardt G; Plank N; Littmann T; Schmidt P; Yi C; Li B; Ye S; Zhang R; Xu B; Larhammar D; Stevens RC; Huster D; Meiler J; Zhao Q; Beck-Sickinger AG; Buschauer A; Wu B
Nature; 2018 Apr; 556(7702):520-524. PubMed ID: 29670288
[TBL] [Abstract][Full Text] [Related]
2. Dimeric argininamide-type neuropeptide Y receptor antagonists: chiral discrimination between Y1 and Y4 receptors.
Keller M; Kaske M; Holzammer T; Bernhardt G; Buschauer A
Bioorg Med Chem; 2013 Nov; 21(21):6303-22. PubMed ID: 24074877
[TBL] [Abstract][Full Text] [Related]
3. BODIPY-conjugated neuropeptide Y ligands: new fluorescent tools to tag Y1, Y2, Y4 and Y5 receptor subtypes.
Dumont Y; Gaudreau P; Mazzuferi M; Langlois D; Chabot JG; Fournier A; Simonato M; Quirion R
Br J Pharmacol; 2005 Dec; 146(8):1069-81. PubMed ID: 16231000
[TBL] [Abstract][Full Text] [Related]
4. Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family.
Cabrele C; Beck-Sickinger AG
J Pept Sci; 2000 Mar; 6(3):97-122. PubMed ID: 10759209
[TBL] [Abstract][Full Text] [Related]
5. Modeling of neuropeptide receptors Y1, Y4, Y5, and docking studies with neuropeptide antagonist.
Jois SD; Nagarajarao LM; Prabhakaran M; Balasubramaniam A
J Biomol Struct Dyn; 2006 Apr; 23(5):497-508. PubMed ID: 16494499
[TBL] [Abstract][Full Text] [Related]
6. Evidence that the inhibition of luteinizing hormone secretion exerted by central administration of neuropeptide Y (NPY) in the rat is predominantly mediated by the NPY-Y5 receptor subtype.
Raposinho PD; Broqua P; Pierroz DD; Hayward A; Dumont Y; Quirion R; Junien JL; Aubert ML
Endocrinology; 1999 Sep; 140(9):4046-55. PubMed ID: 10465275
[TBL] [Abstract][Full Text] [Related]
7. N(ω)-Carbamoylation of the Argininamide Moiety: An Avenue to Insurmountable NPY Y1 Receptor Antagonists and a Radiolabeled Selective High-Affinity Molecular Tool ([(3)H]UR-MK299) with Extended Residence Time.
Keller M; Weiss S; Hutzler C; Kuhn KK; Mollereau C; Dukorn S; Schindler L; Bernhardt G; König B; Buschauer A
J Med Chem; 2015 Nov; 58(22):8834-49. PubMed ID: 26466164
[TBL] [Abstract][Full Text] [Related]
8. Mutagenesis of human neuropeptide Y/peptide YY receptor Y2 reveals additional differences to Y1 in interactions with highly conserved ligand positions.
Akerberg H; Fällmar H; Sjödin P; Boukharta L; Gutiérrez-de-Terán H; Lundell I; Mohell N; Larhammar D
Regul Pept; 2010 Aug; 163(1-3):120-9. PubMed ID: 20471432
[TBL] [Abstract][Full Text] [Related]
9. Structural basis of neuropeptide Y signaling through Y1 receptor.
Park C; Kim J; Ko SB; Choi YK; Jeong H; Woo H; Kang H; Bang I; Kim SA; Yoon TY; Seok C; Im W; Choi HJ
Nat Commun; 2022 Feb; 13(1):853. PubMed ID: 35165283
[TBL] [Abstract][Full Text] [Related]
10. Ligands of the neuropeptide Y Y2 receptor.
Mittapalli GK; Roberts E
Bioorg Med Chem Lett; 2014 Jan; 24(2):430-41. PubMed ID: 24365162
[TBL] [Abstract][Full Text] [Related]
11. Regulation of neuropeptide Y release by neuropeptide Y receptor ligands and calcium channel antagonists in hypothalamic slices.
King PJ; Widdowson PS; Doods HN; Williams G
J Neurochem; 1999 Aug; 73(2):641-6. PubMed ID: 10428060
[TBL] [Abstract][Full Text] [Related]
12. Identification of positions in the human neuropeptide Y/peptide YY receptor Y2 that contribute to pharmacological differences between receptor subtypes.
Fällmar H; Åkerberg H; Gutiérrez-de-Terán H; Lundell I; Mohell N; Larhammar D
Neuropeptides; 2011 Aug; 45(4):293-300. PubMed ID: 21696823
[TBL] [Abstract][Full Text] [Related]
13. Binding of chimeric NPY/galanin peptides M32 and M242 to cloned neuropeptide Y receptor subtypes Y1, Y2, Y4, and Y5.
Berglund MM; Saar K; Lundell I; Langel U; Larhammar D
Neuropeptides; 2001; 35(3-4):148-53. PubMed ID: 11884204
[TBL] [Abstract][Full Text] [Related]
14. Structural basis for Y2 receptor-mediated neuropeptide Y and peptide YY signaling.
Kang H; Park C; Choi YK; Bae J; Kwon S; Kim J; Choi C; Seok C; Im W; Choi HJ
Structure; 2023 Jan; 31(1):44-57.e6. PubMed ID: 36525977
[TBL] [Abstract][Full Text] [Related]
15. Novel analogues of neuropeptide Y with a preference for the Y1-receptor.
Söll RM; Dinger MC; Lundell I; Larhammer D; Beck-Sickinger AG
Eur J Biochem; 2001 May; 268(10):2828-37. PubMed ID: 11358498
[TBL] [Abstract][Full Text] [Related]
16. Modeling the G-protein-coupled neuropeptide Y Y1 receptor agonist and antagonist binding sites.
Du P; Salon JA; Tamm JA; Hou C; Cui W; Walker MW; Adham N; Dhanoa DS; Islam I; Vaysse PJ; Dowling B; Shifman Y; Boyle N; Rueger H; Schmidlin T; Yamaguchi Y; Branchek TA; Weinshank RL; Gluchowski C
Protein Eng; 1997 Feb; 10(2):109-17. PubMed ID: 9089810
[TBL] [Abstract][Full Text] [Related]
17. Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor.
Sautel M; Rudolf K; Wittneben H; Herzog H; Martinez R; Munoz M; Eberlein W; Engel W; Walker P; Beck-Sickinger AG
Mol Pharmacol; 1996 Aug; 50(2):285-92. PubMed ID: 8700135
[TBL] [Abstract][Full Text] [Related]
18. A Y2 receptor mimetic aptamer directed against neuropeptide Y.
Proske D; Höfliger M; Söll RM; Beck-Sickinger AG; Famulok M
J Biol Chem; 2002 Mar; 277(13):11416-22. PubMed ID: 11756401
[TBL] [Abstract][Full Text] [Related]
19. Irreversible binding kinetics of neuropeptide Y ligands to Y2 but not to Y1 and Y5 receptors.
Dautzenberg FM; Neysari S
Pharmacology; 2005 Dec; 75(1):21-9. PubMed ID: 15908753
[TBL] [Abstract][Full Text] [Related]
20. Distribution of [Leu31,Pro34]NPY-sensitive, BIBP3226-insensitive [125I]PYY(3-36) binding sites in rat brain: possible relationship to Y5 NPY receptors.
Widdowson PS; Buckingham R; Williams G
Brain Res; 1997 Dec; 778(1):242-50. PubMed ID: 9462897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
